Northern Rivers Capital Management logo

Northern Rivers Capital Management

North America, Ontario, Canada, Toronto

Description

Northern Rivers Capital Management is a private equity company that invests and advises U.S.-based public equity companies.

Investor Profile

Northern Rivers Capital Management has backed more than 1 startups, with 0 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 2 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Post Ipo Equity rounds (top funding stages).
  • Majority of deals are located in United States.
  • Strong thematic focus on Biopharma, Biotechnology, Pharmaceutical.

Stage Focus

  • Post Ipo Equity (100%)

Country Focus

  • United States (100%)

Industry Focus

  • Biopharma
  • Biotechnology
  • Pharmaceutical
  • Therapeutics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Northern Rivers Capital Management frequently co-invest with?

Iroquois Capital
North America, Tennessee, United States, Nashville
Co-Investments: 1
TH
North America, California, United States, Menlo Park
Co-Investments: 1
LA
North America, Pennsylvania, United States, Philadelphia
Co-Investments: 1
InterGroup
Oceania, Auckland, New Zealand, Auckland
Co-Investments: 1
Alpha Capital
North America, Illinois, United States, Chicago
Co-Investments: 1
Heights Capital Management
North America, California, United States, San Francisco
Co-Investments: 1
Midsummer Capital
North America, New York, United States, New York
Co-Investments: 1
Defiance Capital
North America, New York, United States, New York
Co-Investments: 1
NV
North America, Illinois, United States, Deerfield
Co-Investments: 1
Perceptive Advisors
North America, New York, United States, New York
Co-Investments: 1

What are some of recent deals done by Northern Rivers Capital Management?

Sevion Therapeutics

San Diego, California, United States

Sevion is a biopharmaceutical company which discovers and develops entirely new therapeutic classes for the treatment of cancer.

BiopharmaBiotechnologyPharmaceuticalTherapeutics
Post Ipo EquityMar 29, 2010
Amount Raised: $11,500,000